COMMUNIQUÉS West-GlobeNewswire

Aicuris Presents Positive Phase 2 Results for Pritelivir and Favorable Phase 1 Safety Data for AIC468 at ID Week 2025
20/10/2025
Results from pritelivir Phase 2 study demonstrate a favorable safety profile and a numerically higher lesion healing rate vs. foscarnet Pritelivir Phase 2 results supported FDA Breakthrough Therapy Designation and [...]
The Ensign Group Schedules Third Quarter Earnings Call for Tuesday, November 4, 2025
20/10/2025
SAN JUAN CAPISTRANO, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign TM group of companies, which invest in and provide skilled nursing and senior living [...]
Biodesix to Report Third Quarter 2025 Financial Results on November 3, 2025
20/10/2025
LOUISVILLE, Colo., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the third quarter ended September 30 [...]
Keros Therapeutics Commences Issuer Tender Offer to Repurchase up to $194.4 Million Shares
20/10/2025
LEXINGTON, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel [...]
RadNet, Inc. Announces Date of its Third Quarter 2025 Financial Results Conference Call
20/10/2025
LOS ANGELES, Oct. 20, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT) , a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient [...]
Disc Medicine Provides Update on Hematology Portfolio and Outlines Near-Term Business Objectives and Anticipated Milestones
20/10/2025
Submitted a New Drug Application (NDA) for accelerated approval of bitopertin in erythropoietic protoporphyria (EPP) on September 29, 2025, and subsequently was awarded the FDA Commissioner’s National Priority Voucher ( [...]
WeightWatchers Collaborates With Amazon Pharmacy to Increase Medication Delivery Speed, Convenience and Savings For Members
20/10/2025
NEW YORK, Oct. 20, 2025 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“WeightWatchers” or the “Company”), the global leader in science-backed weight management, today announced a collaboration with Amazon [...]
BioCryst to Report Third Quarter 2025 Financial Results on November 3
20/10/2025
RESEARCH TRIANGLE PARK, N.C., Oct. 20, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its third quarter 2025 financial results on Monday, November 3, [...]
Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
20/10/2025
WATERTOWN, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments [...]
J-Star Applauds the Cooperation of Nasdaq and Ho Chi Minh City to Develop an International Financial Center in Vietnam
20/10/2025
TAICHUNG CITY, Taiwan, Oct. 20, 2025 (GLOBE NEWSWIRE) -- J-Star Holding Co., Ltd. (Nasdaq: YMAT) (“J-Star” or the “Company”), a leading provider of innovative carbon fiber and composite solutions across a wide range of [...]
BPGbio and Icahn School of Medicine at Mount Sinai Publish Landmark Study on the Living Human Brain, Unlocking New Molecular Insights Into Neurodegenerative Disease
20/10/2025
New findings challenge the longstanding assumption that postmortem tissue accurately represents the living brain — and can reshape the future of research and drug development for Alzheimer’s, Parkinson’s, and other [...]
Medicenna Therapeutics Announces Participation in Upcoming Conferences
20/10/2025
TORONTO and HOUSTON, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of [...]
Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma
20/10/2025
Prescription Drug User Fee Act (PDUFA) target action date set for April 10, 2026 WOBURN, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering [...]
New One-Year Data Reinforcing the Robust and Sustained Efficacy of EMPAVELI® (pegcetacoplan) in C3G and Primary IC-MPGN to be Presented at ASN Kidney Week
20/10/2025
Significant proteinuria reduction maintained at one year, regardless of immunosuppressant use or baseline proteinuria levels Complete proteinuria remission ( UPCR ≤0.5 g/g) achieved in one-third of patients and [...]
Humber River Health Celebrates 10-Year Anniversary of Wilson Site
20/10/2025
Built on a vision of being lean, green and digital TORONTO, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Humber River Health proudly marks the 10 th anniversary of its Wilson Site, a decade since opening North America’s first [...]
Communiqué de presse : Le vaccin antigrippal à haute dose de Sanofi démontre une protection supérieure contre les hospitalisations chez les séniors par rapport aux vaccins à dose standard
20/10/2025
Le vaccin antigrippal à haute dose de Sanofi démontre une protection supérieure contre les hospitalisations chez les séniors par rapport aux vaccins à dose standard Par rapport aux vaccins antigrippaux à dose standard, [...]
Press Release: Sanofi’s high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose
20/10/2025
Sanofi’s high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose Compared to standard-dose influenza vaccines, Efluelda/Fluzone High-Dose demonstrated a [...]
FDA approves Roche’s Gazyva/Gazyvaro for the treatment of lupus nephritis
20/10/2025
FDA approval based on superiority of Gazyva/Gazyvaro over standard therapy alone, as shown in phase II NOBILITY and phase III REGENCY data 1,2 Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody to demonstrate a [...]
Roche’s Tecentriq showed significant overall and disease-free survival benefits in bladder cancer with ctDNA-guided treatment
20/10/2025
Tecentriq reduced the risk of death by 41% and the risk of disease recurrence or death by 36% compared with placebo 1 IMvigor011 is the first global phase III study to read out pioneering a ctDNA- guided approach to [...]

Pages